Takeda moves novel prostate cancer drug into Phase III
This article was originally published in Scrip
Executive Summary
Takeda has begun an international Phase III clinical trial programme with its novel prostate cancer drug TAK-700, an oral non-steroidal inhibitor of androgen synthesis.